Abstract
In small studies and cases series, a history of tuberculosis has been associated with both airflow obstruction, which is characteristic of chronic obstructive pulmonary disease, and restrictive patterns on spirometry. The objective of the present study was to assess the association between a history of tuberculosis and airflow obstruction and spirometric abnormalities in adults.
The study was performed in adults, aged 40 years and above, who took part in the multicentre, cross-sectional, general population-based Burden of Obstructive Lung Disease study, and had provided acceptable post-bronchodilator spirometry measurements and information on a history of tuberculosis. The associations between a history of tuberculosis and airflow obstruction and spirometric restriction were assessed within each participating centre, and estimates combined using meta-analysis. These estimates were stratified by high- and low/middle-income countries, according to gross national income.
A self-reported history of tuberculosis was associated with airflow obstruction (adjusted odds ratio 2.51, 95% CI 1.83–3.42) and spirometric restriction (adjusted odds ratio 2.13, 95% CI 1.42–3.19).
A history of tuberculosis was associated with both airflow obstruction and spirometric restriction, and should be considered as a potentially important cause of obstructive disease and low lung function, particularly where tuberculosis is common.
Abstract
Tuberculosis should be considered a potentially important risk factor for obstructive disease and low lung function http://ow.ly/Ns4vR
Footnotes
This article has supplementary material available from erj.ersjournals.com
Support statement: The BOLD Study is funded by a grant from the Wellcome Trust (085790/Z/08/Z). The initial BOLD programme was funded in part by unrestricted educational grants to the Operations Center in Portland, OR, USA, from ALTANA, Aventis, AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Merck, Novartis, Pfizer, Schering-Plough, Sepracor and the University of Kentucky. Additional local support for BOLD sites was provided by: Boehringer Ingelheim China (Guangzhou, China); the Turkish Thoracic Society, Boehringer-Ingelheim and Pfizer (Adana, Turkey); Altana, Astra-Zeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck Sharpe and Dohme, Novartis, Salzburger Gebietskrankenkasse and the Salzburg Local Government (Salzburg, Austria); Research for International Tobacco Control, the International Development Research Centre, the South African Medical Research Council, the South African Thoracic Society, a GlaxoSmithKline Pulmonary Research Fellowship and the University of Cape Town Lung Institute (Cape Town, South Africa); Landspítali University Hospital Scientific Fund, GlaxoSmithKline Iceland and AstraZeneca Iceland (Reykjavik, Iceland); GlaxoSmithKline Pharmaceuticals, Polpharma, Ivax Pharma Poland, AstraZeneca Pharma Poland, ZF Altana Pharma, Pliva Kraków, Adamed, Novartis Poland, Linde Gaz Polska, Lek Polska, Tarchomińskie Zakłady Farmaceutyczne Polfa, Starostwo Proszowice, Skanska, Zasada, Agencja Mienia Wojskowego w Krakowie, Telekomunikacja Polska, Biernacki, Biogran, Amplus Bucki, Skrzydlewski, Sotwin and Agroplon (Krakow, Poland); Boehringer-Ingelheim, and Pfizer Germany (Hannover, Germany); the Norwegian Ministry of Health's Foundation for Clinical Research, and Haukeland University Hospital's Medical Research Foundation for Thoracic Medicine (Bergen, Norway); AstraZeneca, Boehringer-Ingelheim, Pfizer and GlaxoSmithKline (Vancouver, BC, Canada); Marty Driesler Cancer Project (Lexington, KY, USA); Altana, Boehringer Ingelheim (Phil), GlaxoSmithKline, Pfizer, Philippine College of Chest Physicians, Philippine College of Physicians and United Laboratories (Phil) (Manila, Philippines); Air Liquide Healthcare P/L, AstraZeneca P/L, Boehringer Ingelheim P/L, GlaxoSmithKline Australia P/L and Pfizer Australia P/L (Sydney, Australia); the Department of Health Policy Research Programme and Clement Clarke International (London, UK); Boehringer Ingelheim and Pfizer (Lisbon, Portugal); the Swedish Heart and Lung Foundation, The Swedish Association against Heart and Lung Diseases and GlaxoSmithKline (Uppsala, Sweden); GlaxoSmithKline, AstraZeneca and Eesti Teadusfond (Estonian Science Foundation) (Tartu, Estonia); AstraZeneca and CIRO HORN (Maastricht, The Netherlands); Sher-i-Kashmir Institute of Medical Sciences, Srinagar and J&K (Srinagar, India); the Foundation for Environmental Medicine, Kasturba Hospital and the Volkart Foundation (Mumbai, India); Boehringer Ingelheim (Sousse, Tunisia); Boehringer Ingelheim (Fes, Morocco); Philippines College of Physicians, Philippines College of Chest Physicians, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Orient Euro Pharma, Otsuka Pharma and United laboratories Philippines (Nampicuan and Talugtug, Philippines); National Heart and Lung Institute, Imperial College, London (Pune, India); The Wellcome Trust, and the National Population Commission, Ile-Ife, Osun State, Nigeria (Ile-Ife, Nigeria); the Kyrgyz Thoracic Society (Bishkek, Kyrgyzstan); GlaxoSmithKline (Tirana, Albania); GSK, the Liverpool School of Tropical Medicine and the Malawi Liverpool Wellcome Trust (Blantyre, Malawi); The Saudi Thoracic Society and King Abdullah International Medical Research Center KAIMRC (Riyadh, Saudi Arabia); Salmawit Pharmaceuticals and Medical International Company Limited, and The Epidemiological Laboratory (Khartoum, Sudan); Boehringer Ingelheim (Annaba, Algeria); GlaxoSmithKline Pharmaceutical Sdn. Bhd. (Penang, Malaysia); and the BRAC Health Nutrition and Population Programme (Dhaka, Bangladesh). Funding information for this article has been deposited with FundRef.
Conflict of interest: Disclosures can be found alongside the online version of this article at erj.ersjournals.com
- Received December 11, 2014.
- Accepted May 1, 2015.
- Copyright ©ERS 2015